Androgenetic Alopecia (AGA)
Conditions
Keywords
androgenetic alopecia, dihydroartemisinin
Brief summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Interventions
DRUGOral DHA + Topical minoxidil 5%
DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
Topical minoxidil 5% daily for 180 days
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Clinically diagnosed with androgenetic alopecia (AGA) * No pregnancy plans within the next 6 months
Exclusion criteria
* Patients who received systemic medications for hair loss within the past 2 months * Use of topical medication for hair loss within the past 2 weeks * Pregnancy or lactation * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in terminal hair follicles in the vertex area | Baseline and 180-day of treatment | Terminal hair follicles in the vertex area will be quantified before and at the end of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of terminal hair follicle density in the vertex area from baseline to the end of treatment | Baseline and 180-day of treatment | — |
| Change of hair density in the vertex area from baseline to the end of treatment | Baseline and 180-day of treatment | — |
| Change of terminal hair follicle density in the frontal area from baseline to the end of treatment | Baseline and 180-day of treatment | Terminal hair follicle density in the frontal area |
| Change of hair density in the frontal area from baseline to the end of treatment | Baseline and 180-day of treatment | — |
| Change of serum total testosterone from baseline to the end of treatment | Baseline and 180-day of treatment | — |
Countries
China
Contacts
Primary ContactLujuan GAO, MD, PhD
Outcome results
None listed